Related papers: A Survival Mediation Model with Bayesian Model Ave…
Radiation Therapy (XRT) is one of the most common cancer treatment methods. In this paper, a new mathematical model is proposed for the population dynamics of heterogeneous tumor cells following external beam radiation treatment. According…
The assessment of imaging biomarkers is critical for advancing precision medicine and improving disease characterization. Despite the availability of methods to derive disease heterogeneity metrics in imaging studies, a robust framework for…
As cancer patient survival improves, late effects from treatment are becoming the next clinical challenge. Chemotherapy and radiotherapy, for example, potentially increase the risk of both morbidity and mortality from second malignancies…
We present a phase-space analysis of a mathematical model of tumor growth with an immune responses. We consider mathematical analysis of the model equations with multipoint initial condition regarding to dissipativity, boundedness of…
Background: Radiotherapy outcomes are usually predicted using the Linear Quadratic model. However, this model does not integrate complex features of tumor growth, in particular cell cycle regulation. Methods: In this paper, we propose a…
Unscheduled treatment interruptions may lead to reduced quality of care in radiation therapy (RT). Identifying the RT prescription dose effects on the outcome of treatment interruptions, mediated through doses distributed into different…
Aims: Combinations of treatments can offer additional benefit over the treatments individually. However, trials of these combinations are lower priority than the development of novel therapies, which can restrict funding, timelines and…
In recent years, mixture cure models have gained increasing popularity in survival analysis as an alternative to the Cox proportional hazards model, particularly in settings where a subset of patients is considered cured. The proportional…
We consider a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects which is introduced in [2]. It is comprised of phase-field equation to describe tumor growth, which is coupled to a…
In semicompeting risks problems, nonterminal time-to-event outcomes such as time to hospital readmission are subject to truncation by death. These settings are often modeled with illness-death models for the hazards of the terminal and…
In this paper, a Bayesian approach is developed for simultaneously comparing multiple experimental treatments with a common control treatment in an exploratory clinical trial. The sample size is set to ensure that, at the end of the study,…
In cancer translational research, increasing effort is devoted to the study of the combined effect of two drugs when they are administered simultaneously. In this paper, we introduce a new approach to estimate the part of the effect of the…
Precision medicine promises to transform health care by offering individualised treatments that dramatically improve clinical outcomes. A necessary prerequisite is to identify subgroups of patients who respond differently to different…
The difference in restricted mean survival time (RMST) is a clinically meaningful measure to quantify treatment effect in randomized controlled trials, especially when the proportional hazards assumption does not hold. Several frequentist…
We present a model for the interaction dynamics of lymphocytes-tumor cells population. This model reproduces all known states for the tumor. Futherly,we develop it taking into account periodical immunotheraphy treatment with cytokines…
The evolutionary and ecological dynamics of tumors under immune responses and therapeutic interventions pose major challenges to long-term treatment success. Although treatment may initially achieve short-term disease control, resistant…
Multi-gene panel testing allows many cancer susceptibility genes to be tested quickly at a lower cost making such testing accessible to a broader population. Thus, more patients carrying pathogenic germline mutations in various…
Comparing the survival times among two groups is a common problem in time-to-event analysis, for example if one would like to understand whether one medical treatment is superior to another. In the standard survival analysis setting, there…
Despite the fact that cancer survivability rates vary greatly between stages, traditional survival prediction models have frequently been trained and assessed using examples from all combined phases of the disease. This method may result in…
This study employs a robust analytical framework to uncover patterns in survival outcomes among breast cancer patients from diverse racial and geographical backgrounds. This research uses the SEER 2021 dataset to analyze breast cancer…